Granted Patent
B2
US 12,201,675 · App. 16/562,494 · Granted Jan 21, 2025
Methods and products for nucleic acid production and delivery
Assignee:
Factor Bioscience Inc.
A61K38/39A61B18/18A61G19/00A61K8/606A61K9/0019A61K9/0021A61K9/127A61K31/573A61K31/575A61K31/7068A61K31/7072A61K31/7105A61K31/711A61K31/713A61K38/38A61K38/44A61K38/45A61K45/06A61K47/46A61K48/00A61K48/005A61Q19/008A61Q19/06A61Q19/08C12N15/87A61B2018/00452A61B2018/1807A61K2800/83A61K2800/91
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
Claims (32)
1. An in vivo method for treating dystrophic epidermolysis bullosa, comprising
delivering a synthetic RNA encoding a gene-editing protein that targets a COL7 gene to a patient in need thereof and
delivering a COL7 repair template to the patient, thereby editing the COL7 gene, wherein:
the synthetic RNA and the COL7 repair template are delivered to the patient's keratinocytes by injection to the epidermis.
2. The method of claim 1 , wherein the gene-editing protein corrects or eliminates, either alone or in combination with one or more other molecules or gene-editing proteins, a mutation that is at least partially responsible for a disease phenotype.
3. The method of claim 1 , wherein the COL7 repair template is a single-stranded DNA molecule or a double-stranded DNA molecule.
4. The method of claim 1 , wherein the COL7 repair template does not contain a binding site of the gene-editing protein.
5. The method of claim 1 , wherein the gene-editing protein targets a nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 78.
6. The method of claim 1 , wherein the gene-editing protein is selected from the group consisting of a nuclease, a transcription activator-like effector nuclease (TALEN), a zinc-finger nuclease, a meganuclease, a nickase, and a clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein.
7. The method of claim 1 , wherein the synthetic RNA molecule further comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.
8. The method of claim 1 , wherein the synthetic RNA and the COL7 repair template are delivered to a part of the skin that is disrupted or removed.
9. The method of claim 8 , wherein the disrupted or removed part of the skin is the stratum corneum.
10. The method of claim 1 , wherein the injection comprises a patch configured to deliver a nucleic acid to the epidermis.
11. The method of claim 10 , wherein the patch comprises a micro-needle array.
12. The method of claim 11 , wherein at least two needles in the micro-needle array form part of a high-voltage circuit.
13. The method of claim 12 further comprising applying a transient electric field in the vicinity of the keratinocytes.
14. The method of claim 1 , wherein the synthetic RNA and the COL7 repair template are not directed to the patient's dermis and/or wherein the synthetic RNA and the repair template are not directed to the patient's fibroblasts.
15. An in vivo method for treating epidermolysis bullosa, comprising
delivering a synthetic RNA encoding a gene-editing protein that targets a COL7 gene to a patient in need thereof and
inducing a single-stranded or double-stranded break in the COL7 gene of the patient's keratinocytes, thereby eliminating a mutation that is at least partially responsible for a disease phenotype, wherein:
the synthetic RNA is delivered to the patient's keratinocytes by injection to the epidermis.
16. The method of claim 15 , wherein the gene-editing protein is capable of targeting a nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 78.
17. The method of claim 15 , wherein the gene-editing protein is selected from the group consisting of a nuclease, a transcription activator-like effector nuclease (TALEN), a zinc-finger nuclease, a meganuclease, a nickase, and a clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein.
18. The method of claim 15 , wherein the synthetic RNA further comprises one or both of a 5′-cap structure and a 3′-poly(A) tail.
19. The method of claim 15 , wherein the synthetic RNA further comprises one or both of a 5′-cap 1 structure and a 3′-poly(A) tail.
20. The method of claim 15 , wherein the synthetic RNA is delivered to a part of the skin that is disrupted or removed.
21. The method of claim 20 , wherein the disrupted or removed part of the skin is the stratum corneum.
22. The method of claim 15 , wherein the injection comprises a patch configured to deliver a nucleic acid to the epidermis.
23. The method of claim 22 , wherein the patch comprises a micro-needle array.
24. The method of claim 23 , wherein at least two needles in the micro-needle array form part of a high-voltage circuit.
25. The method of claim 24 further comprising applying a transient electric field in the vicinity of the keratinocytes.
26. The method of claim 15 , wherein the synthetic RNA is not directed to the patient's dermis and/or wherein the synthetic RNA is not directed to the patient's fibroblasts.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 10, 2019
From: ANGEL, MATTHEW; ROHDE, CHRISTOPHER
To: FACTOR BIOSCIENCE INC.
Reel/Frame 050326/0596 →
Continuity (7)
Continuation
14761461
Provisional Application
62069667
· Oct 28, 2014
Provisional Application
62038608
· Aug 18, 2014
Provisional Application
61934397
· Jan 31, 2014
References Cited (313)
US 3539465A
· Jensen et al.
· 1970
[cited by applicant]
US 5843780A
· Thomson
· 1998
[cited by applicant]
US 7276489B2
· Agrawal et al.
· 2007
[cited by applicant]
US 7442548B2
· Thomson et al.
· 2008
[cited by applicant]
US 7449334B2
· Thomson et al.
· 2008
[cited by applicant]
US 7621606B2
· Page et al.
· 2009
[cited by applicant]
US 7682828B2
· Jaenisch et al.
· 2010
[cited by applicant]
US 7687266B2
· Chambers et al.
· 2010
[cited by applicant]
US 7812000B2
· Agrawal et al.
· 2010
[cited by applicant]
US 8048675B1
· Irion
· 2011
[cited by applicant]
US 8048999B2
· Yamanaka et al.
· 2011
[cited by applicant]
US 8058065B2
· Yamanaka et al.
· 2011
[cited by applicant]
US 8071369B2
· Jaenisch et al.
· 2011
[cited by applicant]
US 8129187B2
· Yamanaka et al.
· 2012
[cited by applicant]
US 8202850B2
· Agrawal et al.
· 2012
[cited by applicant]
US 8278036B2
· Kariko et al.
· 2012
[cited by applicant]
US 8420782B2
· Bonas et al.
· 2013
[cited by applicant]
US 8440431B2
· Voytas et al.
· 2013
[cited by applicant]
US 8440432B2
· Voytas et al.
· 2013
[cited by applicant]
US 8450471B2
· Voytas et al.
· 2013
[cited by applicant]
US 8470973B2
· Bonas et al.
· 2013
[cited by applicant]
US 8586526B2
· Gregory et al.
· 2013
[cited by applicant]
US 8691966B2
· Kariko et al.
· 2014
[cited by applicant]
US 8710200B2
· Schrum et al.
· 2014
[cited by applicant]
US 8716465B2
· Rossi et al.
· 2014
[cited by applicant]
US 8748089B2
· Kariko et al.
· 2014
[cited by applicant]
US 8802438B2
· Rossi et al.
· 2014
[cited by applicant]
US 8822663B2
· Schrum et al.
· 2014
[cited by applicant]
US 8835108B2
· Kariko et al.
· 2014
[cited by applicant]
US 8883506B2
· Rossi et al.
· 2014
[cited by applicant]
US 9393257B2
· Osborn
· 2016
[cited by examiner]
US 9770489B2
· Angel et al.
· 2017
[cited by applicant]
US 20030009148A1
· Hayakawa
· 2003
[cited by applicant]
US 20030083272A1
· Wiederholt et al.
· 2003
[cited by applicant]
US 20050053588A1
· Yin
· 2005
[cited by applicant]
US 20050130144A1
· Nakatsuji et al.
· 2005
[cited by applicant]
US 20070134796A1
· Holmes et al.
· 2007
[cited by applicant]
US 20080213377A1
· Sangeeta et al.
· 2008
[cited by applicant]
US 20090029465A1
· Thomson et al.
· 2009
[cited by applicant]
US 20090093433A1
· Woolf et al.
· 2009
[cited by applicant]
US 20090275128A1
· Thomson et al.
· 2009
[cited by applicant]
US 20100047261A1
· Hoerr et al.
· 2010
[cited by applicant]
US 20100075421A1
· Yamanka et al.
· 2010
[cited by applicant]
US 20100120079A1
· Page et al.
· 2010
[cited by applicant]
US 20100168000A1
· Kiessling et al.
· 2010
[cited by applicant]
US 20100184033A1
· West et al.
· 2010
[cited by applicant]
US 20100272695A1
· Agulnick et al.
· 2010
[cited by applicant]
US 20100273220A1
· Yanki et al.
· 2010
[cited by applicant]
US 20110045001A1
· Klosel et al.
· 2011
[cited by applicant]
US 20110065103A1
· Sahin et al.
· 2011
[cited by applicant]
US 20110171185A1
· Klimanskaya et al.
· 2011
[cited by applicant]
US 20110189137A1
· Rana et al.
· 2011
[cited by applicant]
US 20110236978A1
· Stolzing et al.
· 2011
[cited by applicant]
US 20110239315A1
· Bonas et al.
· 2011
[cited by applicant]
US 20110263015A1
· D'Costa et al.
· 2011
[cited by applicant]
US 20120195936A1
· Rudolph et al.
· 2012
[cited by applicant]
US 20120237975A1
· Schrum et al.
· 2012
[cited by applicant]
US 20130040302A1
· Burke et al.
· 2013
[cited by applicant]
US 20130102034A1
· Schrum et al.
· 2013
[cited by applicant]
US 20130123481A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130156849A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130165504A1
· Bancel et al.
· 2013
[cited by applicant]
US 20130189741A1
· Meis et al.
· 2013
[cited by applicant]
US 20130217119A1
· Bonas et al.
· 2013
[cited by applicant]
US 20130244282A1
· Schrum et al.
· 2013
[cited by applicant]
US 20130245103A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20140073053A1
· Yanik et al.
· 2014
[cited by applicant]
US 20140194482A1
· Farber et al.
· 2014
[cited by applicant]
US 20140242154A1
· Montandi
· 2014
[cited by applicant]
US 20180271951A1
· Angel et al.
· 2018
[cited by applicant]
CN 101200758
· 2008
[cited by applicant]
EP 2241572
· 2010
[cited by applicant]
EP 2320952
· 2011
[cited by applicant]
JP 2003306448
· 2003
[cited by applicant]
JP 2013086009A
· 2013
[cited by applicant]
KR 20140035133A
· 2012
[cited by examiner]
WO WO9800551A2
· 1998
[cited by applicant]
WO WO199800551
· 1998
[cited by applicant]
WO WO1998030679
· 1998
[cited by applicant]
WO WO0074763A2
· 2000
[cited by applicant]
WO WO2000074763
· 2000
[cited by applicant]
WO WO2002026757
· 2002
[cited by applicant]
WO WO02094251A1
· 2002
[cited by applicant]
WO WO2002094251
· 2002
[cited by applicant]
WO WO2003086472
· 2003
[cited by applicant]
WO WO2007024708
· 2007
[cited by applicant]
WO WO2008065381
· 2008
[cited by applicant]
WO WO2009127230
· 2009
[cited by applicant]
WO WO2009147400
· 2009
[cited by applicant]
WO WO2010012472
· 2010
[cited by applicant]
WO WO2010093655
· 2010
[cited by applicant]
WO WO2010123501
· 2010
[cited by applicant]
WO WO2010148050
· 2010
[cited by applicant]
WO WO2010130447
· 2010
[cited by applicant]
WO WO2011071931
· 2011
[cited by applicant]
WO WO2011071936
· 2011
[cited by applicant]
WO WO2011110886
· 2011
[cited by applicant]
WO WO2011114237
· 2011
[cited by applicant]
WO WO2011012316
· 2011
[cited by applicant]
WO WO2011130624
· 2011
[cited by applicant]
WO WO2011140397
· 2011
[cited by applicant]
WO WO2011141820
· 2011
[cited by applicant]
WO WO2011154393
· 2011
[cited by applicant]
WO WO2012019122
· 2012
[cited by applicant]
WO WO2012019168
· 2012
[cited by applicant]
WO WO2012036299
· 2012
[cited by applicant]
WO WO2012048213
· 2012
[cited by applicant]
WO WO2012060473
· 2012
[cited by applicant]
WO WO2012122318
· 2012
[cited by applicant]
WO WO2012131090
· 2012
[cited by applicant]
WO WO2012131090A1
· 2012
[cited by applicant]
WO WO2012138453
· 2012
[cited by applicant]
WO WO2012174224
· 2012
[cited by applicant]
WO WO2012174224A2
· 2012
[cited by applicant]
WO WO2012176015
· 2012
[cited by applicant]
WO WO2012176015A1
· 2012
[cited by applicant]
WO WO2013003475
· 2013
[cited by applicant]
WO WO2013009825A1
· 2013
[cited by applicant]
WO WO2013020064
· 2013
[cited by applicant]
WO WO2013053819
· 2013
[cited by applicant]
WO WO2013053819A1
· 2013
[cited by applicant]
WO WO2013086008
· 2013
[cited by applicant]
WO WO2013086008A1
· 2013
[cited by applicant]
WO WO2013102203
· 2013
[cited by applicant]
WO WO2013151671
· 2013
[cited by applicant]
WO WO2013163296
· 2013
[cited by applicant]
WO WO2013173248
· 2013
[cited by applicant]
WO WO2014015314
· 2014
[cited by applicant]
WO WO2014134412
· 2014
[cited by applicant]
WO WO2014190361
· 2014
[cited by applicant]
WO WO2015038075
· 2015
[cited by applicant]
WO WO2015117021A1
· 2015
[cited by applicant]
McIvor, S. Therapeutic Delivery of mRNA: The Medium Is the Message. Mol Therapy, 19:822-823, 2011. (Year: 2011).
[cited by examiner]
Hsu et al., Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer (PNAS, 2011, 108:15816-15821) (Year: 2011).
[cited by examiner]
Alexander et al., Liposome-mediated gene transfer and expression via the skin (Hum Mol Gen, 1995, 4:2279-2285) (Year: 1995).
[cited by examiner]
Zheng et al., Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation (PNAS, 2012, 109: 11975-11980) (Year: 2012).
[cited by examiner]
Woodley et al., Intradermal Injection of Lentiviral Vectors Corrects Regenerated Human Dystrophic Epidermolysis Bullosa Skin Tissue in Vivo (Mol Therapy, 2004, 10:318-326 (Year: 2004).
[cited by examiner]
“Xeno-Free System for hESC & hiPSC. Facilitating the Shift from Stem Cell Research to Clincal Applications.” 12 pages, Biological Industries Catalog (Stem Cell Products) (2011).
[cited by applicant]
Albumax I product insert, Invitrogen Corporation (Jun. 2001).
[cited by applicant]
Anderson et al., “Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation,” Nucl. Acids Res. 38(17), pp. 1-9 (2010).
[cited by applicant]
Anderson et al., “Nucleofection induces transient eiF2a phosphorylation by GCN2 and PERK,” Gene Ther., pp. 1-7 (Feb. 2, 2012).
[cited by applicant]
Anderson et al., “Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L,” Nucl. Acids Res. 39(21), pp. 9329-9338 (2011).
[cited by applicant]
Angel et al., “Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins,” PLoS One, vol. 5(7), e11756, pp. 1-7 (Jul. 2010).
[cited by applicant]
Angel, “Extended Transient Transfection by Repeated Delivery of an In Vitro-Transcribed RNA,” Master of Science in Electrical Engineering and Computer Science, 56 pages (Massachusetts Institute of Technology, Cambridge,…
[cited by applicant]
Angel, “Reprogramming Human Somatic Cells to Pluripotency Using RNA”, pp. 1-89 (Ph.D. diss., Massachusetts Institute of Technology) (Feb. 2012).
[cited by applicant]
Angel, “Reprogramming human somatic cells to pluripotency using RNA,” Doctor of Philosophy in Electrical Engineering and Computer Science, 55 pages (Massachusetts Institute of Technology, Cambridge, Massachusetts) (Oct.…
[cited by applicant]
Arnold et al., “Reprogramming of Human Huntington Fibroblasts Using mRNA,” ISRN Cell Biology 2012: Article ID 124878, pp. 1-12 (2012).
[cited by applicant]
Barker et al., “A method for the deionization of bovine serum albumin,” Tissue Culture Association, pp. 111-112 (1975).
[cited by applicant]
Berg, “Proposed structure for the zinc-binding domains from transcription factor IIIA and related proteins,” Proc. Natl. Acad. Sci. USA, vol. 85, pp. 99-102 (Jan. 1988).
[cited by applicant]
Boch et al., “Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors,” Science, vol. 3126, pp. 1509-1512 (Dec. 11, 2009).
[cited by applicant]
Bolli et al., “Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial,” Lancet, pp. 1-11 (Nov. 14, 2011).
[cited by applicant]
Braam et al., “Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self-renewal via au β5 integrin,” Stem Cells 26, pp. 2257-2265 (2008).
[cited by applicant]
Carroll, “Progress and prospects: Zinc-finger nucleases as gene therapy agents,” Gene Therapy, vol. 15, pp. 1463-1468 (2008).
[cited by applicant]
Chen et al., “Chemically defined conditions for human iPSC derivation and culture,” Nat. Methods 8, pp. 424-429 (May 2011).
[cited by applicant]
Chen et al., “Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics,” Cell Res. 21, pp. 884-894 (2011).
[cited by applicant]
Christian et al., “Targeting DNA Double-Strand Breaks with TAL Effector Nucleases,” Genetics, vol. 186, pp. 757-761 (Oct. 2010).
[cited by applicant]
Cui et al., “Targeted integration in rat and mouse embryos with zinc-finger nucleases,” Nat. Biotech., vol. 29, No. 1, pp. 64-67 (Jan. 2011).
[cited by applicant]
Davis, “Stabilization of RNA stacking by pseudouriding,” Nucleic Acids Research, vol. 23, No. 24, pp. 5020-5026 (1995).
[cited by applicant]
Droge et al., “A comparative study of some physico-chemical properties of human serum albumin samples from different sources-I. Some physico-chemical properties of isoionic human serum albumin solutions,” Biochem. Pharm…
[cited by applicant]
Efe et al., “Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy,” Nat. Cell Biol. 13, pp. 215-222 (Mar. 2011).
[cited by applicant]
Fritsch et al., “Dominant-negative Effects of COL7A1 Mutations can be Rescued by Controlled Overexpression of Normal Collagen VII,” The Journal of Biological Chemistry, vol. 284, No. 44, pp. 30248-30256, Oct. 30, 2009.
[cited by applicant]
Garcia-Gonzalo et al., “Albumin-associated lipids regulate human embryonic stem cell self-renewal,” PLoS One 3: 31384, pp. 1-10 (Jan. 2008).
[cited by applicant]
Geurts et al., “Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases,” Science, vol. 325, p. 433 (Jul. 24, 2009).
[cited by applicant]
Goldberg et al., “The enzymic synthesis of pseudouridine triphosphate,” Biochim. Biophys. Acta, vol. 54, pp. 202-204 (1961).
[cited by applicant]
Goldberg et al., “The incorporation of 5-ribosyluracil triphosphate into RNA in nuclear extracts of mammalian cells,” Biochem. Biophys. Res. Commun. 6, pp. 394-398 (1961).
[cited by applicant]
Goldberg, “Ribonucleic acid synthesis in nuclear extracts of mammalian cells grown in suspension culture; effect of ionic strength and surface-active agents,” Biochim. Biophys. Acta, vol. 51, pp. 201-204 (1961).
[cited by applicant]
Goto et al., “Fibroblasts Show More Potential as Target Cells than Keratinocytes in COL7A1 Gene Therapy of Dystrophic Epidermolysis Bullosa”, J. of Investigative Dermatology (2006) 126, 766-772.
[cited by applicant]
Goto et al., “Targeted Skipping of a Single Exon Harboring a Premature Termination Codon Mutation: Implications and Potential for Gene Correction Therapy for Selective Dystrophic Epidermolysis Bullosa Patients,” J. of I…
[cited by applicant]
Gurung et al., “β-Catenin Is a Mediator of the Response of Fibroblasts to Irradiation,” The American Journal of Pathology, vol. 174, No. 1, pp. 248-255 (Jan. 2009).
[cited by applicant]
Hamanaka et al., “Generation of Germline-Component Rat Induced Pluripotent Stem Cells,” PlosOne, vol. 6, Issue7, pp. 1-9 (Jul. 2011).
[cited by applicant]
Hockemeyer et al., “Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases,” Nature Biotechnology, vol. 27, No. 9, pp. 851-857 (Sep. 2009).
[cited by applicant]
Hockemeyer et al., “Genetic engineering of human ES and iPS cells using TALE nucleases,” Author Manuscript, available in PMC Feb. 1, 2012. Published in final edited form as: Nat Biotechnol.; 29(8): 731-734.
[cited by applicant]
International Search Report, PCT/US2013/068118, 4 pages (Mar. 27, 2014).
[cited by applicant]
International Search Report, PCT/US15/13949, May 21, 2015, 4 pages.
[cited by applicant]
Kahan et al., “The Role of Deoxyribonucleic Acid in Ribonucleic Acid Synthesis,” The Journal of Biological Chemistry, fol. 237, No. 12, pp. 3778-3785 (Dec. 1962).
[cited by applicant]
Kariko et al., “Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA,” Nucl. Acids Res., pp. 1-10 (Sep. 2, 2011).
[cited by applicant]
Kariko et al., “In vivo protein expression from mRNA delivered into adult rat brain,” J. Neurosci. Methods 105, pp. 17-86 (2001).
[cited by applicant]
Kariko et al., “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability,” Mol. Ther. 16, pp. 1833-1840 (2008).
[cited by applicant]
Kariko et al., “Increased Erythropoiesis in Mice Injected with Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin,” Mol. Ther. 20, pp. 948-953 (May 2012).
[cited by applicant]
Kariko et al., “mRNA is an endogenous ligand for Toll-like receptor 3,” J. Biol. Chem. 279, pp. 12542-12550 (2004).
[cited by applicant]
Kariko et al., “Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development,” Drug Discovery & Development, vol. 10, No. 5, pp. 523-532 (2007).
[cited by applicant]
Kariko et al., “Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA,” Immunity 23, pp. 165-175 (2005).
[cited by applicant]
Kawamata et al., “Generation of genetically modified rats from embryonic stem cells,” PNAS, vol. 107, No. 32, pp. 14223-14228 (Aug. 10, 2010).
[cited by applicant]
Kern et al., “Mechanisms of Fibroblast Cell Therapy for Dystrophic Epidermolysis Bullosa: High Stability of Collagen VII Favors Long-term Skin Integrity,” Molecular Therapy, vol. 17, No. 9, pp. 1605-1615, Sep. 2009.
[cited by applicant]
Kim et al. “Direct reprogramming of human neural stem cells by OCT4,” Nature 461, pp. 649-653 (Oct. 2009).
[cited by applicant]
Kim et al. “Oct4-induced pluripotency in adult neural stem cells,” Cell 136, pp. 411-419 (Feb. 6, 2009).
[cited by applicant]
Kim et al., “Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins,” Cell Stem Cell 4, pp. 472-476 (Jun. 5, 2009).
[cited by applicant]
Kim et al., “Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain,” Proc. Natl. Acad. Sci. USA, vol. 93, pp. 1156-1160 (Feb. 1996).
[cited by applicant]
Kim et al., “Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors,” Nature 154, pp. 1-6 (2008).
[cited by applicant]
Lee et al., “Activation of Innate Immunity Is Required for Efficient Nuclear Reprogramming,” Cell 151, pp. 547-558 (Oct. 26, 2012).
[cited by applicant]
Lin et al., “A chemical platform for improved induction of human iPSCs,” Nature Methods, vol. 6, No. 11, pp. 805-808 (Nov. 2009).
[cited by applicant]
Liu et al., “A Small-Molecule Agonist of the Wnt Signaling Pathway,” Angew. Chem. Int. Ed. 44, pp. 1987-1990 (2005).
[cited by applicant]
Lu et al., “Defined culture conditions of human embryonic stem cells,” PNAS 2006, vol. 103, pp. 5688-5693 (Apr. 11, 2006).
[cited by applicant]
Ludwig et al., “Derivation of human embryonic stem cells in defined conditions,” Nat. Biotechnol. 24, pp. 185-187 (Feb. 2006).
[cited by applicant]
Ludwig et al., “Feeder-independent culture of human embryonic stem cells,” Nat. Methods 3, pp. 637-646 (Aug. 2006).
[cited by applicant]
Mahfouz et al., “De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks,” PNAS vol. 108, No. 6, pp. 2623-2628 (Feb. 8, 2011).
[cited by applicant]
Mayr et al., “Gene Therapy for the COL7A1 Gene” Open access peer-reviewed chapter. https://www.intechopen.com/books/gene-therapy-tools-and-potential-applications/gene-therapy-for-the-col7a1-gene Published Feb. 27, 2013.
[cited by applicant]
Miller et al., “A TALE nuclease architecture for efficient genome editing,” Nature Biotechnology, vol. 29, No. 2, pp. 143-148 (Feb. 2011).
[cited by applicant]
Miller et al., “An improved zinc-finger nuclease architecture for highly specific genome editing,” Nat. Biotechnol.; vol. 25, No. 7, pp. 778-785 (Jul. 2007).
[cited by applicant]
MIT Thesis Record, “Reprogramming human somatic cells to pluripotency using RNA,” (Matthew Angel, author) (May 15, 2012).
[cited by applicant]
Moscou et al., “A Simple Cipher Governs DNA Recognition by TAL Effectors,” Science, vol. 326, p. 1501 (Dec. 11, 2009).
[cited by applicant]
Murauer et al., “Functional Correction of Type VII Collagen Expression in Dystrophic Epidermolysis Bullosa,” Journal of Investigative Dermatology, vol. 131, pp. 74-83, 2011.
[cited by applicant]
Ng et al., “A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies,” Nat. Protoc. 3, pp. 768-776 (Apr. 10, 2…
[cited by applicant]
Okita et al., “Generation of germline-competent induced pluripotent stem cells,” Nature, vol. 448, pp. 313-317 (Jul. 19, 2007).
[cited by applicant]
Osborn et al., “TALEN-based Gene Correction for Epidermolysis Bullosa,” Molecular Therapy, vol. 21, No. 6, pp. 1151-1159, Jun. 2013.
[cited by applicant]
Plews et al., “Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach,” PLoS One 5:e14397, pp. 1-10 (Dec. 2010).
[cited by applicant]
Porteus et al., “Gene targeting using zinc finger nucleases,” Nat. Biotechnol., vol. 23, No. 8,, pp. 967-973 (2005).
[cited by applicant]
Potter et al., “Transfection by Electroporation,” Curr Protoc Mol Biol., May 2003, Chapter: Unit-.3. doi:10.1002/0471142727 .mb0903s62, pp. 1-12.
[cited by applicant]
Remington et al: “Injection of 1-7 recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa”, Molecular Therapy. vol. 17, No. 1, (2009), pp. 26-33.
[cited by applicant]
Rossi et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IKB kinase,” Nature, vol. 403, pp. 103-108 (Jan. 6, 2000).
[cited by applicant]
Sander et al., “Targeted gene disruption in somatic zebrafish cells using engineered TALENs,” Author Manuscript, available in PMC on Feb. 5, 2012. Published in final edited form as: Nat Biotechnol.; 29(8): 697-698.
[cited by applicant]
Sanjana et al., “A transcription activator-like effector toolbox for genome engineering,” Nature Protocols, vol. 7, No. 1, pp. 171-192 (2012).
[cited by applicant]
Scheider et al., “An effective method for defatting albumin using resin columns,” Biochim. Biophys. Acta, 221; 376-378 (1970).
[cited by applicant]
Schwartz et al., “Embryonic stem cell trials for macular degeneration: a preliminary report,” Lancet, pp. 1-8; Jan. 23, 2012).
[cited by applicant]
Shimizu et al., “Transformation by Wnt Family Proteins Correlates with Regulation of β-Catenin,” Cell Growth & Differentiation, vol. 8, pp. 1349-1358 (Dec. 1997).
[cited by applicant]
Soldner et al., “Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations,” Author Manuscript, available in PMC on Jul. 22, 2012. Published in final edited form as…
[cited by applicant]
Takahashi et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell 131, pp. 1-12 (Nov. 30, 2007).
[cited by applicant]
Takahashi, et al., “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell 126, pp. 1-14 (Aug. 25, 2006).
[cited by applicant]
Tesson et al., “Knockout rats generated by embryo microinjection of TALENs,” Nature Biotechnology, vol. 29, No. 8, pp. 695-696 (Aug. 2011).
[cited by applicant]
Titeux et al., “Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa,” Dermatologic Clinics, vol. 28, pp. 361-366, Feb. 3, 2010.
[cited by applicant]
Tolar, et al., “Patient-Specific Naturally Gene-Reverted Induced Pluripotent Stem Cells in Recessive Dystrophic Epidermolysis Bullosa,” Journal of Investigative Dermatology, vol. 134, pp. 1246-1254, Jan. 9, 2014.
[cited by applicant]
Wally et al., “Spliceosome-Mediated Trans-Splicing: The Therapeutic Cut and Paste,” Journal of Investigative Dermatology, vol. 132, pp. 1959-1966, Apr. 12, 2012.
[cited by applicant]
Warren et al., “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA,” Cell. Stem Cell 7, pp. 1-13 (Nov. 5, 2010).
[cited by applicant]
Watanabe et al., “A ROCK inhibitor permits survival of dissociated human embryonic stem cells,” Nature Biotechnology, vol. 25, No. 6, pp. 681-686 (Jun. 2007).
[cited by applicant]
Wei, et al., “An Electroporation Chip Based on Flexible Microneedle Array for In Vivo Nucleic Acid Delivery,” MEMS, 2014, San Francisco, CA, USA, Jan. 26-30, 2014, pp. 817-820.
[cited by applicant]
Wernig et al., “In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state,” Nature, vol. 448, pp. 317-324 (Jul. 19, 2007).
[cited by applicant]
Wong, et al., “Potential of Fibroblast Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa”, Journal of Investigative Dermatology (2008) 128, 2179-2189.
[cited by applicant]
Wood et al., “Targeted Genome Editing Across Species Using ZFNs and TALENs,” Science, vol. 333, p. 307 (Jul. 15, 2011).
[cited by applicant]
Xie et al., “Newly expressed proteins of mouse embryonic fibroblasts irradiated to be inactive,” Biochem. Biophys. Res. Commun. 315, pp. 581-588 (2004).
[cited by applicant]
Yakubov et al., “Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors,” Biochem. Biophys. Res. Commun. 394, pp. 189-193 (2010).
[cited by applicant]
You et al., “Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis,” The Journal of Cell Biology, vol. 157, No. 3, pp. 429-440 (Apr. 29, 2002).
[cited by applicant]
Young et al., “Background Mutations in Parental Cells Account for Most of the Genetic Heterogeneity of Induced Pluripotent Stem Cells,” Cell Stem Cell 10, pp. 570-582 (May 4, 2012).
[cited by applicant]
Yu et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science 318, pp. 1917-1920 (Dec. 21, 2007).
[cited by applicant]
Zhou et al., “Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins,” Cell Stem Cell 4, pp. 1-4 (May 8, 2009).
[cited by applicant]
Sep. 3, 2019 Restriction Requirement U.S. Appl. No. 16/006,461.
[cited by applicant]
Chen et al., Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32(4):670-675 (2002).
[cited by applicant]
Chung, H.J., et al., “Type VII Collagen: The Anchoring Fibril Protein at Fault in Dystrophic Epidermolysis Bullosa”, Dermatol Clin, 2010, 28, pp. 93-105.
[cited by applicant]
Dang, N., et al., “Mutation analysis and characterization of COL7A1 mutations in epidermolysis bullosa”, Experimental Dermatology, 2008, vol. 17, pp. 553-568.
[cited by applicant]
Fritsch et al., Dominant-negative Effects of COL7A1 Mutations can be Rescued by Controlled Overexpression of Normal Collagen VII. The Journal of Biological Chemistry 284(44):30248-30256 (2009).
[cited by applicant]
Goto et al., Fibroblasts show more potential as Target Cells than Keratinocytes in COL7A1 Gene Therapy of Dystrophic Epidermolysis Bullosa. J of Investigative Dermatology 126: 766-772 (2006).
[cited by applicant]
Goto et al. Targeted Skipping of a Single Exon Harboring a Premature Termination Codon Mutation: Implications and Potential for Gene Correction Therapy for Selective Dystrophic Epidermolysis Bullosa Patients. J of Inves…
[cited by applicant]
Hachiya, A., et al., “Gene transfer in human skin with different pseudotyped HIV-based vectors”, Gene Therapy, 2007, vol. 14, No. 8, pp. 648-656.
[cited by applicant]
Kern et al., Mechanisms of Fibroblast Cell Therapy for Dystrophic Epidermolysis Bullosa: High Stability of Collagen VII Favors Long-Term skin Integrity. Molecular Therapy 17(9): 1605-1615 (2009).
[cited by applicant]
Kuhn, U. et al., “In Vivo Assessment of Gene Delivery to Keratinocytes by Lentiviral Vectors”, Journal of Virology, 2002, vol. 76, No. 3., pp. 1496-1504.
[cited by applicant]
Mayr et al., Gene Therapy for the COL7A1 Gene. Open access peer-reviewed chapter, pp. 561-589 DOI:10.5772/51926 (2013).
[cited by applicant]
Murauer et al., Functional Correction of Type VII Collagen Expression in Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology 131: 74-83 (2011).
[cited by applicant]
NCBI Reference Sequence NP_000085.1 (2013).
[cited by applicant]
Ohmori, T., “The potential of Genome-editing techniques,” Japanese Journal of Thrombosis and Hemostasis, 2015, 26(5), p. 534-540. (Abstract).
[cited by applicant]
Osborn et al., TALEN-based Gene Correction for Epidermolysis Bullosa. Molecular Therapy 21(6): 1151-1159 (2013).
[cited by applicant]
Perdoni, C. et al., “Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa”, Stem Cell Research & Therapy, 2014, 5:121, pp. 1-12.
[cited by applicant]
Potter et al., Transfection by Electroporation. Curr Protoc Mol Biol Chapter: Unit-3, pp. 1-12 (2003).
[cited by applicant]
Remington et al., Injection of 1-7 recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Molecular Therapy 17(1): 26-33 (2009).
[cited by applicant]
Sasaki et al., Mesenchymal Stem Cells are Recruited into Wounded Skin and Contribute to Wound Repair by Transdifferentiation into Multiple Skin Cell Type. J Immuno 180: 2581-2587 (2008).
[cited by applicant]
Schlimgen, R. et al., “Risks Associated with Lentiviral Vector Exposures and Prevention Strategies”, JOEM, vol. 58, No. 12, 2016, pp. 1159-1166.
[cited by applicant]
Titeux et al., Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa. Dermatologic Clinics 28: 361-366 (2010).
[cited by applicant]
Tolar et al., Patient-Specific Naturally Gene-Reverted Induced Pluripotent Stem Cells in Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology 134: 1246-1254 (2014).
[cited by applicant]
U.S. Appl. No. 16/006,461 Final Office Action dated Aug. 16, 2021.
[cited by applicant]
U.S. Appl. No. 16/006,461 Final Office Action dated Jul. 15, 2020.
[cited by applicant]
U.S. Appl. No. 16/006,461 Non-Final Office Action dated Dec. 11, 2019.
[cited by applicant]
U.S. Appl. No. 16/006,461 Non-Final Office Action dated Dec. 24, 2020.
[cited by applicant]
Wally et al., Spliceosome-Mediated Trans-Splicing: The Therapeutic Cut and Paste. Journal of Investigative Dermatology 132: 1959-1966 (2012).
[cited by applicant]
Wei et al., An Electroporation Chip Based on Flexible Microneedle Array for in vivo Acid Delivery. MEMS, San Francisco, CA, Jan. 26-30, pp. 817-820 (2014).
[cited by applicant]
Wong et al., Potential of Fibroblast Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology 128: 2179-2189 (2008).
[cited by applicant]
Aasen et al.: Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature Biotech. 26:1276-1285 (2008).
[cited by applicant]
U.S. Appl. No. 16/006,461 Final Office Action dated Aug. 22, 2022.
[cited by applicant]
U.S. Appl. No. 16/006,461 Office Action dated May 12, 2023.
[cited by applicant]
Aust et al.: Percutaneous Collagen Induction Therapy: An Alternative Treatment for Scars, Wrinkles, and Skin Laxity. Plast Reconstr Surg. 121(4):1421-1429 (2008).
[cited by applicant]
Dupuy et al.: Targeted Gene Therapy of Xeroderma Pigmentosum Cells Using Meganuclease and TALEN&trade. PLoS One. 8(11):e78678 (2013).
[cited by applicant]
European Application No. 22216417.0 extended European Search Report mailed Sep. 22, 2023.
[cited by applicant]
Matsuda et al.: Effects of Ingestion of Collagen Peptide on Collagen Fibrils and Glycosaminoglycans in the Dermis. J Nutr Sci Vitaminol. 52:211-216 (2006).
[cited by applicant]
Potter et al., “Transfection by Electroporation,” Curr Protoc Mol Biol., Chapter: Unit-. 3. doi:10.1002-0471142727.mb0903s62, pp. 1-12,(2003).
[cited by applicant]
U.S. Appl. No. 16/006,461 Final Office Action dated Dec. 21, 2023.
[cited by applicant]